Generic Medicines Industry in India

India’s generic medicines industry combines established manufacturers with a broad base of private companies serving domestic and international healthcare needs.

Top generic medicines companies in India (listed and private)

Frequently asked questions

How large is the generic medicines industry in India?

2052 generic medicines companies with statutory filings (13 listed, 2039 private) reported combined revenue of ₹3.65 lakh crore in FY2025, +8.3% on the same companies, and aggregate EBITDA of ₹75,569 crore. As filed each year, combined revenue was ₹1.57 lakh crore in FY2018, reached ₹3.65 lakh crore in FY2025, the highest in the period; year-on-year changes are measured on the same companies. The 11 listed companies with an exchange price are worth ₹6.47 lakh crore in market capitalisation. Size here is measured in revenue, profit and market value, from statutory filings and exchange prices, not in physical volume of output.

Is profitability improving or deteriorating?

Improving. The aggregate EBITDA margin of generic medicines companies was 20.7% in FY2025, 1.0 pts above FY2024, against a peak of 20.7% in FY2021. The low since the peak was 16.7% in FY2023. Profit after tax margin was 12.4% (+1.6 pts on FY2024). Aggregate EBITDA of listed and private generic medicines companies moved +39% from FY2022 to FY2025 on a same-company basis; FY2025 EBITDA was ₹75,569 crore (+12.5% on FY2024).

Which companies are leading the generic medicines industry?

By FY2025 revenue the largest generic medicines companies are Sun Pharma (₹52,578 crore, 32.8% EBITDA margin); Aurobindo Pharma (₹31,724 crore, 22.7% EBITDA margin); Emami Agrotech (₹16,916 crore, 3.3% EBITDA margin, private); Macleods Pharmaceuticals (₹9,358 crore, 27.2% EBITDA margin, private); MSN Laboratories (₹7,363 crore, 20.4% EBITDA margin, private). Among the ten largest, Aristo Pharmaceuticals (47.8%) and Usv (46.3%) earn the widest EBITDA margins and Emami Agrotech (3.3%) the thinnest. 19 of the 25 largest are private companies, which a listed-only view leaves out.

Where is demand or investment changing?

In the news: Net tone of drug policy stories fell from +11 to -12 (-22 pts) over 323 stories, the largest drop of any theme. In buyer searches: Search interest in generic syrups queries (generic syrup, allopathic syrup, pharmaceutical syrup) was +32% in the 12 months to 2026-09 vs the prior 12, led by “pharmaceutical syrup” (+175%), followed by generic injectables (+9%); generic formulations moved -31%.

What should I investigate next?

These are the findings that fired on the data, negative signals first, each with the topic that holds the evidence: Coverage of drug policy turned more negative (Generic Medicines in the news). Generic Medicines EBITDA grew 39% since FY2022 (Industry financials). 64 private generic medicines manufacturers pass an IPO-readiness screen (Top generic medicines companies in India). Generic syrups searches rose most in the last year (Search & demand signals). Median EV/EBITDA is 19.9× and median P/E 38.5× across 11 priced generic medicines companies. (Market capitalisation & valuation).

How are generic medicines stocks valued?

The median trailing P/E is 38.5× and the median EV/EBITDA 19.9× across 11 priced companies.

What does the generic medicines industry include?

It includes companies that develop, manufacture and distribute off patent medicines for healthcare use.

What matters when assessing generic medicines companies?

Useful considerations include product capability, quality processes, market access, distribution strength and reported financial performance.

Research information, not investment advice.